U.S. FDA approves Johnson & Johnson's blood cancer therapy
Johnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer.
![](https://kbin.cafe/media/cache/resolve/entry_thumb/b7/92/b792dace6ed8444314e0bff69163f83c72564b854660dc3c3403d6bb2ceeed4b.jpg)
Johnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer.